IPVC 2023 workshops will focus on this year’s theme, “Coming Together for HPV Elimination”. They will provide an overview to non-experts on all papillomavirus (PV)-related topics, from basic science to global health impact.

Workshops will be run by and have speakers who are worldwide leaders in the field. They will provide a unique forum for education and discussion.

At IPVC 2023, the workshops will be made up of two parts:

  • The first day will start with two interdisciplinary workshops, consisting of a series of talks covering key aspects of basic science, clinical and public health, with plenty of opportunities for discussion and audience interaction.
  • Thereafter, attendees will be able to join one of the three tracks – Basic Science, Clinical Science or Public Health, Epidemiology and Implementation Science – where specific topics of contemporary interest will be covered. A particular emphasis will be given to discussion on controversial areas of research and on experiences across different populations. In all sessions, audience interaction will be prioritized.

Although workshops stand alone as an educational and scientific activity, they are designed to provide the necessary scientific background to follow the main Conference, where the latest knowledge in research will be presented. For junior scientists, the workshops will help them to be educated on both the basics and cutting-edge knowledge of papillomavirus biology, epidemiology, and prevention and control of papillomavirus infection and disease.

IPVC 2023 workshops will be a unique way to connect across the fields, and attendees will enjoy PV research from different perspectives and participate in wider scientific discussions.

Monday, April 17, 2023

Click on the sections below to learn more about the workshops. Please note the information might be subject to change.

08:00 – 09:30 EDT (GMT -4)

Interdisciplinary Workshop 1: Epidemiology and Basic Science of HPV Infection and Related Diseases

Session Topic: Statistics on cervical cancer, Epidemiology of HPV infection, Experience of cancer patients, and Mechanisms of HPV carcinogenesis.

Session Description: Human papillomavirus (HPV) is sexually transmitted, and its persistent infection is causally associated with the development of cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers. This interdisciplinary session will review the latest global status of HPV-related cancers with real-life stories of cancer survivors, highlighting the urgency of cancer prevention and treatment. The basic mechanisms of cancer development due to HPV infection will also be presented to enhance understanding of clinical strategies for detecting and preventing HPV-associated cancers. 

Learning Objectives:

  • Listen to the real voices of cancer patients and understand the importance of HPV-related cancer control.
  • Understand the current epidemiology of HPV infections and related diseases, including cervical, other anogenital, and head-and-neck cancers.
  • Understand the basic molecular mechanisms of HPV-induced cancer development.

Chair: Suzanne Garland (Australia)
Chair: Toshiyuki Sasagawa (Japan)

  Patient Experience (4 Pre-recorded Stories)
1) Cervix- Busisiwe Moyo (Zimbabwe)
2) Anal- Lillian Kreppel (USA)
3) Oropharynx – Julie McCrossin (Australia)
4) Penile- Patrick Howard (USA)

Global HPV-Driven Cancer: The Global Perspective
 Silvia de Sanjosé (Spain)

The Epidemiology of HPV Infection
 Talia Malagón (Canada)

Basic Mechanisms of HPV Carcinogenesis

  John Doorbar (UK)

10:00 – 11:30 EDT (GMT -4)

  Interdisciplinary Workshop 2: HPV Cancer Prevention: From Basic Science to Real-World Benefits

Session Topic: Immunology of HPV infection and vaccination, prevention of HPV-driven cancers via vaccination and screening including a focus on sexual and gender minorities.

Session Description: The success of the HPV vaccine is a prime example of the application of basic science achievements to clinical practice and public health interventions. The prophylactic vaccines comprising HPV L1 virus-like particles (VLPs) have shown remarkable efficacy against infection and disease caused by vaccine HPV types and are now beginning to have a real-world impact on cervical cancer incidence among vaccinated women. The high efficacy of the HPV vaccine is attributed to the long-lasting, anti-HPV antibody response induced by VLP vaccination. For many reasons, cervical cancer screening will remain a critical approach to controlling cervical cancer.

This session will present the latest understanding of HPV immunology and vaccinology, and summarize the current status and future of both HPV vaccination and cervical screening for eliminating cervical cancer. Additionally, how to prevent HPV-related cancers in sexual and gender minority populations (including but not limited to people who identify as lesbian, gay, bisexual, transgender, and non-binary) will be discussed. 

Learning Objectives:

  • Understanding cellular and humoral immunological responses induced by HPV natural infection and vaccination.
  • Catch up on the current status of HPV vaccination and discuss future prospects.
  • Catch up on the current status of cervical screening and discuss future prospects.
  • Recognize the importance of expanding HPV prevention to minority groups.

  Chair: Anna-Barbara Moscicki (USA)

Chair: John Doorbar (UK)

Basic Immunology of HPV Natural Infection and Vaccination
 Denise Galloway (USA)

HPV Vaccination: Past, Present and Future
 Joakim Dillner (Sweden)

Cervical Cancer Screening: Past, Present and Future
 Rolando Herrero (Costa Rica)

HPV-Cancer Prevention In Sexual and Gender Minorities
 Heather Brandt (USA)

14:00 – 15:30 EDT (GMT -4)

Basic Science Workshop 1: Natural History of HPV Infection and Cancer Development

Chair: Nagayasu Egawa (UK)
Chair: John Doorbar (UK)

Chair Introduction
Nagayasu Egawa (UK)

Cervix and Cervical Cancer
John Doorbar (UK)

Low-Risk HPV and Recurrent Respiratory Papillomatosis
Bettie Steinberg (USA)

Cutaneous HPV Infection
Nagayasu Egawa (UK)

Re-Detection: Re-infection or Re-activation and Does It Matter?
 Patti Gravitt (USA)

16:00 – 17:30 EDT (GMT -4)

Basic Science Workshop 2: Carcinogenesis

Chair: Elizabeth White (USA)
Chair: Karl Munger (USA)

Chair Introduction
Karl Munger(USA)

E7 and Keratinocyte Biology
Elizabeth White (USA)

Long Non-Coding RNA
Karl Munger (USA)

Microbiome and Cervical Carcinogenesis
Maria Kyrgiou (UK)

14:00 – 15:30 EDT (GMT -4)

Clinical Science Workshop 1: Recent Developments in Screening Programs for HPV-Related Cancers

Chair: Eiko Saitoh Aoki  (Japan)

Chair: Silvia de Sanjose (Spain)

Current Status of Screening Programs in Developed and Developing Countries
Silvia de Sanjose (Spain)

Screening for Anal Cancer Precursors- Has The Time Come?
Joel Palefsky (USA)

New Technologies for Screening in Developed and Developing Country Settings
Megan Clarke (USA)

Impact of HPV Vaccination on Screening Programs
Laia Bruni (Spain)

Local View: Screening Programs In Japan
Eiko Saitoh Aoki  (Japan)

14:00 – 17:30 EDT (GMT -4)

Clinical Science Workshop 2: Epidemiology of HPV-Related Cancer and Pre-Cancer In The Vaccine Era

Chair: Eduardo Franco (Canada)

Chair: Sharon Hanley (Japan)

Current Epidemiology of Cervical Cancer and Pre-cancer
 Eduardo Franco (Canada)

Current Epidemiology of Head and Neck Cancer
Anil Chaturvedi-Share (USA)

Current Epidemiology of Anal Cancer and Pre-Cancer
Ann Burchell (Canada)

Current Epidemiology of Other HPV-Related Cancers
Iacopo Baussano (France)

Local View: HPV-Related Cancer In Japan
Sharon Hanley (Japan)

14:00 – 15:30 EDT (GMT -4)

Public Health Workshop 1: HPV Vaccination for Prevention of Cervical Cancer

Chair: Aimee Kreimer (USA)
Chair: Sharon Hanley (UK)

State of The Science on HPV Vaccination
Ruanne Barnabas (USA)

Global Vaccination Uptake by World Region and Projections for Impact
Laia Bruni (Spain)

HPV Vaccination to Prevent Invasive Cervical Cancer
Jaimie Shing (USA)

Vaccine Safety Update
Kristine McCartney (USA)

Local View: Japan Re-introduction of HPV Vaccination
Sharon Hanley (UK)

16:00 – 17:30 EDT (GMT -4)

Public Health Workshop 2: Cervical Cancer Screening

Chair: Talía Malagón (Canada)
Chair: Nico Wentzensen (USA)

State of the Science on Cervical Cancer Screening
Marc Steben (Canada)

Overview of Epidemiologic Methods: Sensitivity, Specificity, Predictive Value and Risk-Based Triaging
Nico Wentzensen (USA)

Managing Screen Positives In LMIC
Ana Cecilia Rodriguez (Costa Rica)

Compliance with Cervical Cancer Screening: Linkages to Precancer Treatment and Follow-up in LMICs
Vikrant Sahasrabuddhe (USA)

Local View: Successful Cervical Cancer Prevention in Malaysia
Yin Ling Woo (Malaysia)

Tuesday, April 18, 2023

Click on the sections below to learn more about the workshops. Please note the information might be subject to change.

08:30 – 10:00 EDT (GMT -4)

Basic Science Workshop 3: Exploring Targets for Antivirals

Chair: Zhi-Ming Zheng (USA)
Chair: Cary Moody (USA)

Chair Introduction
Zhi-ming Zheng
Transcription, Replication
Zhi-Ming Zheng (USA)
Stefan Schwartz (Sweden)
DNA Damage Response
Cary Moody (USA)

Cell Entry

Daniel DiMaio (USA)

10:30 – 12:00 EDT (GMT -4)

Basic Science Workshop 4: HPV Genomics and Evolution

Chair: Lisa Mirabello
Chair: Koenraad Van Doorslaer (USA)

Chair Introduction
Koenraad Van Doorslaer
HPV Genetic Diversity, APOBEC Mutagenesis
Lisa Mirabello (USA)

PV Evolution
Koenraad Van Doorslaer (USA)

Non-Human Primate PV
Zugui Chen (Hong Kong)

HPV Integration

Alix Warburton (USA)

14:30 – 16:00 EDT (GMT -4)

Basic Science Workshop 5: Tissue and Animal Models

Chair: Thomas Broker (USA)
Chair: Jiafen Hu (USA)

Chair Introduction
Thomas Broker (USA)
Three-Dimensional Tissue Models
Thomas Broker (USA)
Cervical Adenocarcinoma Model
Jiafen Hu
Rabbit PV Model
Jiafen Hu (USA)
Mouse PV Model
Paul Lambert (USA)

08:30 – 10:00 EDT (GMT -4)

Clinical Science Workshop 3: HPV Vaccines

Chair: Sharon Hanley (UK)

Landscape of HPV Vaccines: Current and Future
Richard Roden (USA)

Gender-neutral Vaccination: Uptake and Impact
Anna Giuliano (USA)

HPV Vaccine Schedules- Latest Updates

Aimee Kreimer (USA)

HPV Vaccination Among Those Older Than 45 Years
Elmar Joura (Austria)

Local View: HPV Vaccination Program in Japan
Sayaka Ikeda (Japan)

10:30 – 12:00 EDT (GMT -4)

Clinical Science Workshop 4: New Frontiers in Treatment of HPV-Related Cancers and Pre-Cancers

Chair: John Schiller (USA)
Chair: Kei Kawana (Japan)

Recent Developments In Treatment of Cervical Cancer and Cin
Mark Einstein

Recent Developments In Treatment of Anal Cancer and Ain
Andreia Albuquerque (Spain)

Recent Developments In Treatment of Head and Neck Cancer
Jen Kemnade

Update On Therapeutic Vaccines
Kei Kawana (Japan)

Can We and Should We Treat HPV Infection?
John Schiller (USA)

14:30 – 16:00 EDT (GMT -4)

Clinical Science Workshop 5: Management of HPV-Related Disease in Special Populations

Chair: Elizabeth McClymont (Canada)
Chair: Stephen Abbott (USA)

Management of Cervical HPV-Related Disease in Persons Living with HIV
Elizabeth McClymont (Canada)
Management of HPV-Related Anal Disease in People Living with HIV
Joel Palefsky (USA)
Management of HPV-Related Disease in Transplant Recipients and Other Immunosuppressed Hosts
Anna-Barbara Moscicki (USA)
Second HPV-related Cancers
Susanne Krüger Kjær (Denmark)
Management of HPV-Related Disease in Transgender Populations
Stephen Abbott (USA)

08:30 – 10:00 EDT (GMT -4)

Public Health Workshop 3: Worldwide Issues in Cervical Cancer Control

Chair: Yin Ling Woo (Malaysia)
Chair: Nagayasu Egawa (UK)

Behavioral and Social Drivers of HPV vaccination
Noel Brewer (USA)

Modelling Best Approaches: How To Accelerate Cervical Cancer Control
Karen Canfell (Australia)

Screening Implementation Strategies To Meet Who Elimination Targets (Including Self-sampling)
Maribel Almonte (France)

The Importance of Community and Stakeholder Involvement, From The Perspective of Low Resource Settings
Nelly Mugo (Kenya)

Local View: Accelerating Cervical Cancer Control In Japan
Nagayasu Egawa (UK)

10:30 – 12:00 EDT (GMT -4)

Public Health Workshop 4: HPV-Related Cancers Outside of the Cervix

Chair: Laia Alemany (Spain)
Chair: Staci Sudenga (USA)

HPV Attributable Fraction at Non-Cervical Sites
Laia Alemany (Spain)

HPV Vaccine Protection at Non-Cervical Sites
Anna Giuliano (USA)

Anal Cancer Screening-Implementation and Challenges
Joel Palefsky (USA)

Oropharyngeal Cancer- Potential Biomarkers and Diagnostic Work-up
Amber D’Souza (USA)

Oropharyngeal Cancer-Benchmarks for Screening
Hilary Robbins (France)

14:30 – 16:00 EDT (GMT -4)

Public Health Workshop 5: Equity In Cancer Prevention and Control

Chair: Helen Rees (South Africa)
Chair: Yuri Ito (Japan)

Evidence of Inequity: Incidence and Burden of Cervical and Other HPV-related Cancers By Ethnicity and Race. USA-based Analysis Due To Data Availability
Meredith Shiels (USA)

Cervical cancer mortality by education level

Salvatore Vaccarella

HPV Vaccination, Cancer Prevention and Its Associated Challenges In PLWH
Helen Rees (South Africa)

HPV Vaccination, Cancer Prevention and Its Associated Challenges In Indigenous Populations
Beverley Lawton (New Zealand)

HPV Vaccination, Cancer Prevention and Its Associated Challenges In SGM
Sarah Jackson (USA)

Local View: Socioeconomic Inequalities in Cancer Outcome In Japan
Yuri Ito (Japan)

Please note that the workshops for IPVC 2023 are included in the congress fee. No additional fee or pre-registration is required. 

Visit 2021 website Membership